The Special Diabetes Program | Advancing Health Through Research

tochka-krasoty-oficialnyj-sajt

The Special Diabetes Program | Advancing Health Through Research

As NIDDK celebrates its 70th anniversary, we look back on decades of scientific advances. In this video, NIDDK Director Dr. Griffin P. Rodgers details the impact of the Special Diabetes Program on type 1 diabetes research. The Special Statutory Funding Program for Type 1 Diabetes Research, or Special Diabetes Program, is a special appropriation for research on the prevention and cure of type 1 diabetes that the NIDDK administers on behalf of the Secretary of the Department of Health and Human Services, in collaboration with multiple NIH Institutes and Centers and the CDC, and with input from the Diabetes Mellitus Interagency Coordinating Committee. The Special Diabetes Program has enabled the creation of unique, innovative, and collaborative research consortia and clinical trials networks focused on the prevention, treatment, and cure of type 1 diabetes. These consortia have made significant research progress and also generated numerous research resources for use by the broad scientific community. For more information, visit https://www.niddk.nih.gov/about-niddk/70th-anniversary --- Transcript: DR. RODGERS: There is a special committee that I testify to, it's actually the Aging Committee, which is co-chaired by Senator Susan Collins and more recently, on the Democratic side, Senator Casey from Pennsylvania. There it’s set up specifically [to talk about] for a pool of funds called a Special Diabetes Program to focus on Type 1 diabetes.   Senator Collins asked me, “When are you going to be able to develop an artificial pancreas so that these kids won’t have to prick their finger and go through the kinds of very tedious and arduous painstaking way of managing their diabetes?” And I said, “We’re going to work on this.” This was maybe around 2011. In 2016, the FDA approved the very first [hybrid] artificial pancreas. And now there are five additional ones on the market. So we’ve been able to stimulate the biotech industry to really move very quickly in this space, and we’re developing other things that make life living with Type 1 diabetes much more manageable.

НА ГЛАВНУЮ


Поддержите наш сайт.
Поделитесь! Не поленитесь ...

Большое спасибо!